关注
Daniel Y C Heng
Daniel Y C Heng
Tom Baker Cancer Center
在 albertahealthservices.ca 的电子邮件经过验证
标题
引用次数
引用次数
年份
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
23002009
Renal cell carcinoma
JJ Hsieh, MP Purdue, S Signoretti, C Swanton, L Albiges, M Schmidinger, ...
Nature reviews Disease primers 3 (1), 1-19, 2017
22842017
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
12732015
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...
The lancet oncology 17 (7), 917-927, 2016
10492016
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
10482013
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised …
RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ...
The Lancet Oncology 20 (10), 1370-1385, 2019
7262019
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ...
European urology 66 (4), 704-710, 2014
5052014
Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study
HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ...
Journal of Clinical Oncology 35 (34), 3851-3858, 2017
4602017
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy
TK Choueiri, W Xie, C Kollmannsberger, S North, JJ Knox, JG Lampard, ...
The Journal of urology 185 (1), 60-66, 2011
4322011
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first …
JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ...
The lancet oncology 16 (3), 293-300, 2015
3662015
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini, DF McDermott, ...
Journal of Clinical Oncology 32 (15_suppl), 5010-5010, 2014
2912014
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy
AR Golshayan, S George, DY Heng, P Elson, LS Wood, TM Mekhail, ...
Journal of Clinical Oncology 27 (2), 235-241, 2009
2692009
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
RR McKay, N Kroeger, W Xie, JL Lee, JJ Knox, GA Bjarnason, ...
European urology 65 (3), 577-584, 2014
2552014
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database …
N Kroeger, W Xie, JL Lee, GA Bjarnason, JJ Knox, MJ MacKenzie, ...
Cancer 119 (16), 2999-3006, 2013
2342013
Body mass index and metastatic renal cell carcinoma: clinical and biological correlations
L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov, X Lin, JL Lee, ...
Journal of Clinical Oncology 34 (30), 3655-3663, 2016
2202016
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group
J Manola, P Royston, P Elson, JB McCormack, M Mazumdar, S Négrier, ...
Clinical Cancer Research 17 (16), 5443-5450, 2011
2182011
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma
DJ Kwiatkowski, TK Choueiri, AP Fay, BI Rini, AR Thorner, G De Velasco, ...
Clinical Cancer Research 22 (10), 2445-2452, 2016
2172016
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
SK Pal, C Tangen, IM Thompson, N Balzer-Haas, DJ George, DYC Heng, ...
The Lancet 397 (10275), 695-703, 2021
2072021
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib
CJ Richards, Y Je, FAB Schutz, DYC Heng, SM Dallabrida, JJ Moslehi, ...
Journal of clinical oncology 29 (25), 3450-3456, 2011
1862011
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
A Amin, ER Plimack, MS Ernstoff, LD Lewis, TM Bauer, DF McDermott, ...
Journal for immunotherapy of cancer 6, 1-12, 2018
1852018
系统目前无法执行此操作,请稍后再试。
文章 1–20